Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people
Open Access
- 19 March 2009
- journal article
- research article
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 4 (1-2) , 17-23
Abstract
Summary We analysed data from elderly people registered in the Swedish Prescribed Drug Register to investigate whether age is associated with use of osteoporosis drugs in a nationwide population. Our results indicate an undertreatment of osteoporosis, particularly with bisphosphonates, in the oldest old in Sweden. Introduction The aim of this study was to investigate whether age is associated with use of osteoporosis drugs in a large population of older people. Methods We analysed data on age, sex, type of residential area (urban/rural) and dispensed drugs for people aged ≥75 years registered in the Swedish Prescribed Drug Register from October to December 2005 (n = 731,105). Multivariate logistic regression was used to analyse whether age was associated with use of osteoporosis drugs, after adjustment for type of residential area and number of other drugs (a proxy for comorbidity). Results Osteoporosis drugs were used by 16.1% of the women and 3.4% of the men. The probability of use of bisphosphonates declined with increasing age [ORwomen = 0.36 (95% CI 0.34–0.38) and ORmen = 0.46 (95% CI 0.37–0.56) for age ≥90 years vs. 75–79 years]. Raloxifene was also negatively associated with age. Calcium + vitamin D supplements, however, showed a divergent pattern regarding age. In women, the lowest likelihood of use of calcium + vitamin D supplements occurred in the oldest old (≥90 years). Conclusions Our results indicate an undertreatment of osteoporosis, particularly with bisphosphonates, in the oldest old in Sweden. Future research is needed for understanding the mechanisms behind this age effect.Keywords
This publication has 42 references indexed in Scilit:
- Population‐based study of the effectiveness of bone‐specific drugs in reducing the risk of osteoporotic fracturePharmacoepidemiology and Drug Safety, 2008
- European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporosis International, 2008
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006
- Costs and quality of life associated with osteoporosis-related fractures in SwedenOsteoporosis International, 2005
- Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis2005
- Use of cellular telephones and brain tumour risk in urban and rural areasOccupational and Environmental Medicine, 2005
- Cost Effectiveness of Alendronate (Fosamax??) for the Treatment of Osteoporosis and Prevention of FracturesPharmacoEconomics, 2003
- Fracture rates lower in rural than urban communities: the Geelong Osteoporosis StudyJournal of Epidemiology and Community Health, 2002
- Hip fractures in northern Sweden 1973-1984 A comparison of rural and urban populationsActa Orthopaedica, 1989